Filing identity and reporting period
The supplied filing is Trail One, Inc.’s Form 10-K for the fiscal year ended September 30, 2011—not a filing for Citius Pharmaceuticals, Inc. or a standalone 2011 fourth quarter. Trail One was a development-stage Nevada company planning to sell customized aluminum automobile license-plate frames; it had not begun manufacturing or sales.
Financial results and liquidity
| Metric | Fiscal 2011 / September 30, 2011 | Comparison |
|---|---|---|
| Revenue | $0 | $0 for September 9–30, 2010 |
| Net loss | $26,341 | $15,500 for September 9–30, 2010; the prior period was substantially shorter |
| Operating expenses | $25,637: $12,187 general and administrative and $13,450 professional fees | $15,500 professional fees in the 2010 inception period |
| Interest expense | $704 | $0 in the 2010 inception period |
| Cash and total assets | $212 | $2,500 at September 30, 2010 |
| Current liabilities | $24,053, including $18,493 due to a related party and $704 accrued interest | $0 at September 30, 2010 |
| Stockholders’ deficit | $(23,841) | Equity of $2,500 at September 30, 2010 |
| Operating cash flow | $(20,781) | $(15,500) for the 2010 inception period |
Margins are not meaningful because the company had no revenue. The filing reports no material cash interest or income-tax payments. The related-party loans were unsecured, carried 8% interest, and were due on demand. The auditor’s report presents the financial statements fairly in accordance with U.S. GAAP but highlights substantial doubt about the company’s ability to continue as a going concern.
Changes, outlook, and principal risks
The annual net loss rose from the $15,500 loss recorded during the brief 2010 inception period. In fiscal 2011, the company recorded general and administrative costs and interest expense, while reporting no revenue. Cash fell by $2,288 during the year. These periods are not like-for-like because the 2010 comparison covers only September 9–30.
Management expected losses to continue and costs to rise over the next 12 months. It estimated an annual burn rate of about $54,000 and said about $75,000 would be needed to complete steps to market the product. It did not expect sales to cover working-capital needs and said additional equity, debt, or private financing would be necessary. A founder’s oral funding commitment was described as limited and not legally binding; the filing also says there was no loan agreement in place. Financing was not assured, and failure to obtain it could force the company to curtail or cease operations.
Key risks include no operating history or product sales, limited cash, dependence on one intended manufacturer (APMI) without a manufacturing agreement, competition, reliance on founder and CEO Ralph Montrone, potential dilution from future financing, and no established trading market. The filing identifies material weaknesses in internal control over financial reporting and says disclosure controls were ineffective. The board consisted of one director, with no independent directors or audit committee.
Important facts to verify
- Issuer and period: confirm the intended filing is Trail One, Inc. for fiscal 2011; the request metadata names Citius Pharmaceuticals and 2011 Q4.
- Working-capital deficit: the balance sheet and MD&A report $23,841, while a risk-factor passage reports $20,781. Reconcile this discrepancy.
- Ownership: the filing describes the founder as owning about 100% of voting stock in one passage, but a later table reports 10,000,000 of 18,000,000 shares, or 55.6%. Verify beneficial ownership and voting control.
- Funding: verify any subsequent financing, the status and terms of founder support, and the company’s ability to meet demand obligations on related-party debt.
- Execution: confirm whether product manufacturing, the APMI relationship, website development, and sales ever commenced; none had begun as reported.